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Background: Infrastructural inefﬁciencies are a leading reason
infectious diseases retain their endemic status in many resource-
limited settings. Information and communications technologies
(ICT), especiallymobile technologies (mHealth), havegreatpromise
in such settings, where they simultaneously present the highest
potential in terms of enabling technology and have the highest per-
tinence for improving weak healthcare systems.mHealth has been
used for large-scale disease surveillance, remote advice for prac-
titioners, treatment compliance, and supply chain management in
infectious disease programmes, but has found very limited adop-
tion for diagnostics.
Methods & Materials: We studied the landscapes of mHealth
in the diagnostics of three major infectious diseases: HIV, TB and
malaria. From January to July 2013, we analysed reports by global
healthcare actors such as the WHO, WB and Stop TB Partnership,
peer-reviewedpublications related to ICTandhealthcare, andother
references sourced from these publications. The search was for
English language publications only, leading to potential reporting
bias. Taking a new technology-centred approach, we conceptualise
mHealth architectures as three constituent elements: front-end
(user device), back-end (IT infrastructure) and controller which
links the two.
Results: mHealth initiatives have targeted several components
of the diagnostics pathway: Early case-detection, diagnosis and
referral; Adherence to diagnostics protocols during consultations;
Physical and digital transport of samples to diagnostics centres;
Protocol adherence at the diagnostics hubs; Integration of results
upstream into patient records and disease surveillance systems;
Rapid communication of results downstream to the health facilities
and patients. Recent efforts take amore holistic approach including
efforts at automatic reporting of results from diagnostics centres to
points of care, and integration of results into patient records. Some
efforts seek to integrate ICT right into the diagnostics machines or
rapid diagnostics tests.
Conclusion: ICT has signiﬁcant potential to become a major
tool in improving the diagnostics processes of infectious diseases,
though real-world implementations are severely lacking as of now.
Our technology-oriented approach allows us to understand under-
lying features of ‘successful’ mHealth endeavours and delineate a
panel to choose from for future implementations. This panel will
further evolve as broadband networks spread, mobile devices have
reducedcost-per-feature, andapplications leverage increasedcom-
putational capacities of devices for in situ processing.
http://dx.doi.org/10.1016/j.ijid.2014.03.1211
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Background: Brucellosis is a zoonotic disease affecting human
and animal health. Isolation of Brucella organism is the best
approachandgold standard for controlling it.Monospeciﬁcantisera
A and M are used for identiﬁcation and typing of Brucella isolates.
The context of the study is to eliminate the expensive and unac-
ceptable cost of importation or to ensure an efﬁcient test result
avoiding transportation and storage process damages as well as
saving time.
The main objective of this study is to measure the economic
feasibilityofproducingstandardizedBrucellamonospeciﬁcantisera
A and M in Sudan and comparing that with the cost of importing
antisera.
Methods & Materials: Brucella abortus strain 544 and Brucella
melitensis strain 16M live suspensions and non-viable Brucella cell
antigens were prepared. Ten healthy rabbits were intravenously
infected with the viable Brucella suspension. All infected rabbits
serawere titrated against homologous antigen and investigated for
Brucella antibodies level at days 6th, 8th and 11th using Rose Bengal
Plate and serum agglutination tests. Finally all rabbits were bled
intra-cardinally at day 17th and their sera were titrated against
homologous and heterologous antigens using serum agglutination
test.
Heterologous antibodies of sera were absorbed individually
using heterologous non-viable antigens. The two monospeciﬁc
antisera A and M were standardized and then preserved either by
lyophilization or dilution in phenol saline (0.05% phenol and 0.85%
NaCl) at the rate of 1:5.
Keeping quality of the preserved antisera was checked while
stored each in deep freezing, fridge and room temperature
and examination of antibody titers against homologous antigen
monthly for one year.
For measuring the economic feasibility, comparative advantage
method was used.
Results: Sudan had a comparative advantage in producing Bru-
cella monospeciﬁc antisera A and M.
Cost of local production of Brucella monospeciﬁc antisera is sav-
ing more than 50% of its importing cost.
Local production of monospeciﬁc antisera is associated with
high quality and further efﬁcient diagnostic results.
As addition beneﬁt we save time consuming in marketing pro-
cess (foreign currency payment, handling and storage).
Conclusion: Brucella monospeciﬁc antisera A and M have pos-
itive economic impact when produced in Sudan using some local
inputs.
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